Alvotech 与强生公司就 AVT04 生物仿制药达成和解协议。 Alvotech and Johnson & Johnson strike settlement agreements for AVT04 biosimilar.
Alvotech 是一家专门从事生物仿制药的生物技术公司，宣布已与强生公司达成和解协议，将在日本、加拿大和欧洲经济区 (EEA) 推出其生物仿制药 AVT04，即 Stelara® (ustekinumab) 的一个版本。 Alvotech, a biotech company specializing in biosimilar medicines, announced it has reached settlement agreements with Johnson & Johnson to launch its biosimilar AVT04, a version of Stelara® (ustekinumab), in Japan, Canada, and the European Economic Area (EEA). 该公司预计将于 2024 年第一季度进入加拿大市场，并于 2024 年 5 月进入日本市场，目前正在等待当地批准。 The company expects to enter the Canadian market in Q1 2024 and Japan in May 2024, pending local approval. 预计 Stelara 的欧洲补充保护证书将于 2024 年 7 月下旬到期后进入欧洲市场。 Entry to the European markets is anticipated after the expiration of the European Supplementary Protection Certificate for Stelara in late July 2024. Alvotech 已与多家商业实体合作在这些地区推出 AVT04，包括 Fuji Pharma Co. Ltd、JAMP Pharma Group 和 STADA Arzneimittel AG。 Alvotech has partnered with various commercial entities for the launch of AVT04 in these regions, including Fuji Pharma Co. Ltd., JAMP Pharma Group, and STADA Arzneimittel AG.